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Abstract
Stem cells have received considerable attention by the scientiﬁc community because of their potential
for tissue engineering and regenerative medicine. The most frequently used method to promote their
differentiation is supplementation of the in vitro culture medium with growth/differentiation factors
(GDFs). The limitations of that strategy caused by the short half-life of GDFs limit its efﬁcacy in vivo
and consequently its clinical use. Thus, the development of new concepts that enable the bioactivity
and bioavailability of GDFs to be protected, both in vitro and in vivo, is very relevant. Nanoparticle-
based drug delivery systems can be injected, protect the GDFs and enable spatiotemporal release ki-
netics to be controlled. Liposomes are well-established nanodelivery devices presenting signiﬁcant
advantages, viz. a high load-carrying capacity, relative safety and easy production, and a versatile
nature in terms of possible formulations and surface functionalization. The main objective of the
present study was to optimize the formulation of liposomes to encapsulate dexamethasone (Dex).
Our results showed that the optimized Dex-loaded liposomes do not have any cytotoxic effect on human
bonemarrow-derivedmesenchymal stem cells (hBMSCs). More importantly, they were able to promote
an earlier induction of differentiation of hBMSCs into the osteogenic lineage, as demonstrated by the ex-
pression of osteoblastic markers, both phenotypically and genotypically. We concluded that Dex-loaded
liposomes represent a viable nanoparticle strategywith enhanced safety and efﬁcacy for tissue engineer-
ing and regenerative medicine. Copyright © 2013 John Wiley & Sons, Ltd.
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1. Introduction
The advent of nanoscience and nanotechnology in the last
20 years enabled the development of nanoscale devices
that may interact with biological systems at the molecular
level. Those devices may be designed to stimulate, re-
spond to and interact with target cells and tissues at the
subcellular scale of these physiological events. In this
way it is possible to inﬂuence these events locally and to
minimize the undesirable side-effects that are common
in the most traditional systemic strategies (Kim et al.,
2010). Nanoparticles that are currently in clinical use as
drug-release systems or as imaging devices (Kim et al.,
2010) are examples of such devices. As drug-delivery sys-
tems, they allow drugs to be released speciﬁcally at the
intended site of action (Gabizon et al., 1998; Goldberg
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et al., 2007; Tan et al., 2012). Other nanometric drug-
release systems include liposomes, dendrimers and poly-
meric systems (Santo et al., 2010; Shi et al., 2010; Mickova
et al., 2012). The nanoparticle-based systems have the
advantage of diffusing through cytoplasmatic cell mem-
branes, allowing cell activityto be controlled or modiﬁed.
Recently, our group has proposed a strategy based on
tissue-engineering principles and using dendrimer
nanoparticles (CMCht/PAMAM),which has shown capacity
to enable the intracellular release of dexamethasone (Dex;
an osteogenic differentiation factor) (Oliveira et al., 2008,
2009). The local release of Dex was also studied in other
devices, i.e. starch-based microparticles (SPCL) (Balmayor
et al., 2008, 2009a, 2009b) and nanoﬁbres (Martins et al.,
2010), showing consistent positive efﬁcacy in driving the
osteogenic differentiation of stem cells.
Considering our background in the development of
polymer-based nano- and microparticles as drug-release
systems, we proposed the development of lipid-based
nanoparticles or liposomes for the development of cell-
based therapies. Liposomes are well-established carrier
systems (Pjanović et al., 2010), enabling the encapsula-
tion of both hydrophilic and lipophilic compounds
(Bhardwaj and Burgess, 2010); the stability of the lipo-
somes may be enhanced by adding cholesterol in the for-
mulation (Lee et al., 2005). The liposomes can also be
sterically stabilized by using polymer additives, e.g. PEG,
into the formulation. These liposomes are very stable both
during storage and upon injection into the blood plasma
(Loughrey et al., 1993; Song et al., 2009). Liposomes pres-
ent signiﬁcant advantages over other nanoparticle-based
drug-release systems, such as a high load-carrying capac-
ity (Lee et al., 2005; Liu and Park, 2010), low cytotoxicity
(Moreira et al., 2002) and a versatile structure in terms of
possible formulation and functionalization (Drummond
et al., 1999). Various bioactive molecules have been
loaded in lipid-based systems, using a variety of prepara-
tion methods (Almeida and Souto, 2007; Gomes-da-Silva
et al., 2012; Moura et al., 2012). The liposomes can be ad-
ministrated by many routes, such as intravenously (Chono
et al., 2006), orally (Li et al., 2003), by inhalation (Chen
et al., 2012), by local injection (Hegeman et al., 2011) or
by ocular administration (Diebold et al., 2007).
Human mesenchymal stem cells (hMSCs) are adult
stem cells with great potential in different therapeutic
contexts, but particularly for tissue engineering and
regenerative medicine. Those cells can be isolated from
adult tissue sources such as bone marrow, cord blood,
placenta, adipose and dermal tissues, synovial ﬂuid,
deciduous teeth and amniotic ﬂuid (Engler et al., 2006;
Katayama et al., 2006). Moreover, they have the potential
for expansion and the ability to differentiate into various
mesodermal tissues, e.g. bone, cartilage, fat, muscle and
other connective tissues (Huang et al., 2005; Martins
et al., 2010). hMSCs may provide a useful model for eval-
uating the multiple factors responsible for the stepwise
progression of cells from undifferentiated precursors to
secretory osteoblasts and, eventually, terminally differen-
tiated osteocytes (Jaiswal et al., 1997; Park et al., 2007).
The regulation of stem cell differentiation by drugs and
growth factors might enable the fabrication of therapeutic
materials for the delivery of stem cells that are simpler to
use, cost-effective and more easily controlled than the de-
livery systems currently available (Park et al., 2011). The
combination of nanoparticles and hMSCs presents a new
opportunity to develop advanced therapy medicinal prod-
ucts (Park et al., 2007; Oliveira et al., 2009, 2010).
To our best knowledge, no previous reports published
in the literature have explored the possibility of using
Dex-releasing liposomes as a new method to induce the
differentiation of MSCs, either in vitro or in vivo. In this
study we aimed to optimize the incorporation of an osteo-
genic differentiation factor, Dex, into liposomes. Further-
more, we studied the effect of Dex released from the
liposomes on the viability, proliferation, protein synthesis
and differentiation of hBMSCs. By using Dex-loaded lipo-
somes, we expected to release this bioactive agent near to,
or even to internalize it into, the hBMSCs.
2. Experimental
2.1. Development of Dex-loaded liposomes
2.1.1. Materials
Chloroform, dexamethasone (Dex) ammonium molybdate,
Fiske-Subbarow reducer and sepharose CL4B, HEPES
buffer solution (HBS), were reagent grade and purchased
from Sigma-Aldrich. The lipids L-α-phosphatidylethanol-
amine-N-(lissamine rhodamine B sulphonyl; ammonium
salt, egg-transphosphatidylated, chicken) (PE-Rho), 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy
(polyethylene glycol)-2000] (ammonium salt; DSPE–PEG),
cholesterol (ovine wool, > 98%; Chol) and L-α-phosphati-
dylcholine, hydrogenated (Soy; HSPC) were purchased
from Avanti Polar Lipids. Dialysis tubing cellulose mem-
brane (100–500 molecular weight cut off (MWCO), 10 mm
ﬂat width) was purchased from Spectrum Laboratories.
All the materials were used as received.
2.1.2. Production and characterization of
Dex-loaded liposomes
Table 1 shows the liposome formulations used in this
study. Formulations A–D were used to study encapsula-
tion efﬁciency and the effect of adding Chol and Dex to
the liposome bilayer; formulation E was used to perform
the release study of the liposomes from the dialysis tub-
ing; and formulation F was used for biological assays.
Lipids and Dex were mixed in a round-bottomed ﬂask,
withdrawing appropriate amounts of each lipid from the
stock solutions (15 mM total lipid), in the proportions de-
scribed for each type of liposomal formulation. The sol-
vent chloroform was slowly evaporated using a gentle
steam of nitrogen. The obtained dry ﬁlm was dispersed
using vortex agitation with HBS, keeping the temperature
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of the hydrating medium above the gel–liquid crystal
transition temperature (Tc=52°C). The multilamellar
liposomal suspension was extruded (using an Avanti
Mini-Extruder) at T>Tc through a porous polycarbonate
membrane (100 nm). The system was used to force the
solution back and forward (21 times), resulting in
unilamellar liposomes. Non-encapsulated Dex was re-
moved from the solution by column chromatography
(Sepharose CL4B, Sigma-Aldrich), using an isocratic
elution with HBS.
Particle size distribution and ζ -potential were deter-
mined by dynamic light scattering (Zetasizer Nanoseries
ZS, Malvern Instruments). Liposome morphology was
analysed by scanning electron microscopy (SEM) and
scanning transmission electron microscopy (STEM;
NanoSEM Nova 200). The SEM supports were gold-coated
(Cressington 208 HR) before dropping the liposomal solu-
tion onto them. After drying at room temperature, the
SEM supports were coated again with a thin ﬁlm of gold
and palladium (12 nm).
2.1.3. Dex loading efﬁciency into liposomes
The Dex loading efﬁciency was analysed, using formula-
tions A–D, by quantifying Dex and lipid content. Dex con-
centration was determined by UV–VIS spectroscopy at
247 nm (Synergie HT), using Dex-free liposomes as blanks.
The total lipid concentration was assessed by the Bartlett
colorimetric assay, as described elsewhere (Torchilin and
Weissig, 2003). The principle of the Bartlett assay is based
on the colorimetric determination of inorganic phosphate.
The phospholipid content of liposomes can be determined
after destruction of the phospholipid with perchloric acid
to inorganic phosphate. The inorganic phosphate is
converted to phospho-molybdic acid by the addition of
ammoniummolybdate, which is reduced to a blue complex
by 4-amino-2-naphthyl-4-sulphonic acid during heating.
This compound was determined colorimetrically at 830 nm
(Synergie HT).
The ability of the liposomal vesicles to incorporate the
drug was evaluated by calculating the system payload
(PL) from equation (1). The encapsulation efﬁciency
(EE) was calculated as the ﬁnal PL (PLf) per initial PL
(PLi) of Dex and HSPC from equation (2).
PL ¼ amount of Dex molð Þ=amount of HSPC molð Þ (1)
EE %ð Þ ¼ PLf=PLi′  100 (2)
2.1.4. Dex release kinetics from the liposomes
The release of Dex from the loaded liposomes was studied
using a dialysis method. Dialysis cellulose tubes (100–500
MWCO, Spectrum Laboratories) were rinsed with distilled
water for 1 week prior to their use. The tube ends were
closed with Teﬂon tape and Nylon thread and tested for
leakage. 1 ml of each liposomal solution (formulation E,
~17% EE) was added to the dialysis tubes and fully
immersed in 10 ml phosphate-buffered saline (PBS) as
the release medium. Control tubes were assembled using
the same procedure with Dex-free liposomes. The solu-
tions were maintained at 37°C and 60 rpm for 21 days.
For each time point, an aliquot of 1 ml was collected
from the solution and analysed by UV–VIS spectroscopy
at 247 nm (Synergie HT). The same volume of fresh PBS
was replaced to keep the total volume of the release
medium at 10 ml. The Dex concentration in the release
medium was determined based on a standard curve in
the range 0–0.125 mM Dex and the measured values used
to calculate the cumulative release. The experiments were
done in triplicate.
2.2. Biological assays
2.2.1. Expansion, seeding and osteogenic
differentiation of hBMSCs
hBMSCs were isolated from bone marrow aspirates col-
lected under informed consent from patients undergoing
knee arthroplasty at the Hospital de Braga, Portugal.
Samples were collected from a 58 year-old female donor,
isolated, expanded and cryopreserved until further use.
hBMSCs were isolated and characterized according to
the method established by Delorme and Charbord
(2007). Brieﬂy, plastic adherent fractions of marrow cells
characterized by a spindle-shaped morphology and
colony-forming unit (CFU) capacity; expression of surface
antigens such as CD29, CD73, CD90 and CD105, while
negative for haematopoietic markers such as CD34 and
CD45 and by their differentiation potential into the
osteogenic, chondrogenic and adipogenic lineages were
used; all the antibodies were purchased from BD
Pharmingen and the hBMSCs analysed on a FACS Calibur,
BD Biosciences. hBMSCs were expanded in basal medium
consisting of α-minimal essential medium (α-MEM; Gibco,
UK) supplemented with 10% heat-inactivated fetal bovine
serum (FBS; BiochromAG, Germany) and 1% antibiotic–
antimyotic solution (ﬁnal concentration of penicillin
100 U/ml and streptomycin 100 mg/ml; Gibco, UK). The
cells were cultured at 37°C in a humidiﬁed atmosphere
of 5% CO2. The liposomal solutions (formulation F,
~17% EE) were sterilized by 0.22 μm ﬁltering, and 0.5 μl
LipDex was added to 1 ml culture medium. Conﬂuent
hBMSCs at passage 4 were harvested for seeding onto
24-well plates at a density of 1 105 cells. After 24 h of in-
cubation in basal medium, the hBMSCs were cultured on
Dex-free osteogenic differentiation medium (basal medium
Table 1. Liposome formulations (values expressed as a molar
ratio)
Formulation Dex HSPC Chol DSPE-PEG PE-Rho
A 0.25 2 – – –
B 0.50 2 – – –
C 0.25 2 0.1 – –
D 0.25 2 1 – –
E 0.25 2 0.1 0.1 –
F 0.25 2 0.1 0.1 0.02
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supplemented with 50 μg/ml ascorbic acid and 10 mM
β-glycerophosphate) in the presence of Dex-loaded
liposomes. The control condition was cultured on standard
osteogenic differentiation medium (basal medium
supplemented with 50 μg/ml ascorbic acid, 10 mM
β-glycerophosphate and 10–7 M Dex). The cells were
retrieved at predeﬁned culture times (7, 14 and 21 days).
The experiments were performed twice, independently,
with sample triplicates, with hBMSCs from the same donor.
2.2.2. Cell viability and proliferation assessment
Cell viability for each culture condition and time point was
determined using the CellTiter 96® AQueous One Solution
Cell Proliferation Assay (Promega, USA), according to
the manufacturer’s instructions. This assay is based on
the bioreduction of a tetrazolium compound, 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulphofenyl)-2H-tetrazolium (MTS), into a water-soluble
brown formazan product. The absorbance was measured at
490 nm in a microplate reader (SynergieHT, Bio-Tek, USA),
being related to the quantity of formazan product and
directly proportional to the number of living cells in culture.
Four samples/time point were quantiﬁed.
Cell proliferation was quantiﬁed by the total amount of
double-stranded DNA along the culture time. Quantiﬁca-
tion was performed using the Quant-iT™ Pico-Green dsDNA
Assay Kit (Invitrogen™, Molecular Probes™, OR, USA),
according to the manufacturer’s instructions. Brieﬂy, cells
in the construct were lysed by osmotic and thermal shock
and the supernatant used for the DNA quantiﬁcation assay.
The ﬂuorescence of the dye was measured at an excitation
wavelength of 485/20 nm and at an emission wavelength
of 528/20 nm in a microplate reader (Synergie HT, Bio-
Tek; USA). Quadruplicates were made for each sample
and culture time. The DNA concentration for each sample
was calculated using a standard curve (DNA concentration
in the range 0.0–1.5 μg/ml), relating DNA quantity to the
ﬂuorescence intensity.
All data concerning cell viability, proliferation and ALP
activity were independently measured and normalized
against the cell number for each sample. For that, a standard
calibration curve was constructed, using known hBMSCs
cell numbers at passage 4, in the range 0–5  105 cells
(n=12). The dsDNA concentration of these samples was
determined according to the Quant-iT™ PicoGreen dsDNA
reagent previously described. The following equation was
obtained:
y ¼ 0:0054x þ 86:68
where R2=0.998, y is the measured ﬂuorescence value
and x is the cell number, and used to estimate the cell
number for each sample.
2.2.3. Alkaline phosphatase and total protein
quantiﬁcation
The concentration of alkaline phosphatase (ALP) was deter-
mined for all culture periods, using the lysates used for DNA
quantiﬁcation. Brieﬂy, the ALP quantity was assessed using
the p-nitrophenol assay, in which 4-nitrophenyl phosphate
disodium salt hexahydrate (Sigma, USA) is hydrolysed by
intracellular ALP at a temperature of 37°C in an alkaline
buffer solution (1.5 M and pH 10.5; Sigma) to form free,
yellow p-nitrophenol. The reactionwas stopped by the addi-
tion of 0.3 M NaOH (Panreac Quimica, Spain) and the ab-
sorbance read at 405 nm in a microplate reader (Bio-Tek).
Standards were prepared with 10 mM p-nitrophenol (pNP;
Sigma, USA) solution to obtain a standard curve in the
range 0–250 μM. Quadruplicates of each sample and stan-
dard were made, and the ALP concentrations read off the
standard curve.
For the quantiﬁcation of total protein synthesized by
the hBMSCs in culture, the Micro BCA™ Protein Assay kit
(Thermo Scientiﬁc, Pierce; Rockford, USA) was used
according to themanufacturer’s instructions. This is a color-
imetric detection and quantiﬁcation method which utilizes
bicinchoninic acid (BCA) as the detection reagent for
Cu+1 formed when Cu+2 is reduced by the protein in an
alkaline environment. Quadruplicates of lysed cells per cul-
ture time were incubated at 37°C for 2 h. A purple reaction
product was measured at 562 nm in a microplate reader
(Bio-Tek) and calculated based on an albumin standard
curve in the range 0–40 μg/ml.
2.2.4. Immunocytochemistry for bone-speciﬁc
proteins
At predeﬁned culture times, hBMSCs were ﬁxed in 10%
formalin solution neutral buffer (Sigma-Aldrich, Germany).
After an initial washingwith PBS, the cells were treatedwith
0.3% hydrogen peroxide in methanol for 30 min to inacti-
vate the endogenous peroxidases. After washing with PBS,
the cells were blocked with 3% BSA solution for 20 min at
room temperature to avoid non-speciﬁc reactions. Immuno-
cytochemistry was performed using a rabbit polyclonal
antibody against osteopontin (Abcam, Cambridge, UK;
dilution 1:1500) and a mouse monoclonal antibody against
osteocalcin (clone OC4-30, Abcam; dilution 1:100), and an
incubation period of 2 h at room temperature. After washing
in PBS, the samples were incubated for 30 min with
biotinylated secondary antibody anti-rabbit/mouse IgG
(from the R.T.U. Vectastain® Universal Elite ABC kit, Vector
Laboratories, Burlingame, CA, USA), followed by incubation
with streptavidin–peroxidase complex (Elite®ABCReagent;
Vector Laboratories). The immune reaction was visualized
using DAB as a chromogen (DAB Substrate Reagent
from Peroxidase Substract Kit, Vector Laboratories) and
counterstained with Harris’s haematoxylin (Bio-Optica,
Milano, Italy). The slides were observed under an optical
microscope (BX61, Olympus, Germany) and images
captured by a digital camera (DP70, Olympus).
2.2.5. RNA isolation and real-time quantitative
polymerase chain reaction
At each culture time point the hBMSCs were washed with
PBS, immersed in Tri® reagent (Sigma-Aldrich) and stored
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at 80°C until further use. Proteins were removed with
chloroform:isoamylalcohol (BioChemica, AppliChem,
Germany) extraction and the RNA pellets were washed
once with 2-propanol (Sigma-Aldrich) and once with 70%
ethanol (Panreac, Spain). The total RNA pellets were
reconstituted in RNase-free water (Gibco, Invitrogen, UK).
Determination of the RNA concentration for each replica
(quadruplicates of each condition per time point) was
performed by microspectrophotometry (NanoDrop 1000,
Thermo Scientiﬁc, USA).
Reverse-transcriptase (RT)–polymerase chain reaction
(PCR) was performed according to the protocol from
iScript™ cDNA synthesis kit (Quanta BioSciences™,
Gaithersburg, MD, USA). Brieﬂy, a reaction mixture
consisting of 1 iScript Reaction Mix, 1 μl iScript Reverse
Transcriptase, 100–150 ng RNA template and nuclease-free
water was prepared in 20 μl total volume. The single-strand
cDNA synthesis occurred by incubating the complete
reaction mixture for 5 min at 22°C, followed by 30 min at
42°C, and terminated by an incubation at 85°C for 5 min.
Ampliﬁcation of the target cDNA for real-time PCR
quantiﬁcation were performed according to the manufac-
turer’s instructions, using 2 μl RT cDNA product, 250 nM
each primer, 1 PerfeCta® SYBR® Green FasterMix®
(Quanta BioSciences) and nuclease-free water in a ﬁnal
volume of 25 μl. Forty-four cycles of denaturation (95°C,
10 s), annealing (temperature dependent on the gene,
30 s) and extension (72°C, 30 s) were carried out in a
Mastercycler Epgradient SRealplex Thermocycler (Eppendorf,
Hamburg, Germany) for all genes. The transcript expression
data were normalized to the housekeeping gene glyceralde-
hyde-3-phosphate-dehydrogenase (GAPDH) and the quantiﬁ-
cation performed according to the Livak (2–ΔΔCT) method,
considering the tissue culture polystyrene (TCPS)_Osteo
culture condition as the calibrator.
2.2.6. Statistical analysis
Data were statistically analysed using IBM SPSS software
v. 20 (SPSS Inc., USA). We ﬁrst applied the Shapiro–Wilk
test to test the assumption of Normality and the results
showed that the data were not following a Normal distri-
bution. Consequently, the non-parametric Mann–Whitney
U (to test data differences between the TCPS_Osteo and
the TCPS_LipDex conditions) and Kruskal–Wallis (to test
data differences between culture days for each condition)
methods were applied. p< 0.01 was considered statisti-
cally signiﬁcant.
3. Results
3.1. Development and characterization of liposomes
In this study we prepared six different liposomal formula-
tions, including four conventional liposome (CL) formula-
tions (A–D) and two sterically stabilized liposome (SSL)
formulations with DSPE–PEG (E) and SSL with DSPE–PEG
and PE-Rho (F). The CL and SSL formulations differed in
the presence of a polymer coating at the surface of the lipo-
some, most commonly polyethylene glycol (PEG).
3.1.1. Drug encapsulation
PL and EE are presented in Table 2. Analysing the data, it is
demonstrated that the increase of Dex concentration signif-
icantly reduces its encapsulation efﬁciency (p< 0.001),
while the observed variations in the system PL are not sig-
niﬁcant. These results reveal that the maximum encapsula-
tion was reached with a Dex:HSPC ratio of 0.25:2. On
increasing the Chol proportion from 0.0 to 0.1 no signiﬁcant
variations were observed in the system PL; increasing Chol
to 1.0 signiﬁcantly reduced the PL and EE to near-zero
encapsulation. The encapsulation of Dex was higher when
no Chol was added (49 molecules Dex incorporated/100
molecules lipid). With the data obtained in this study,
a compromise was obtained with the formulation
0.25:2.0:0.1 (Dex:HSPC:Chol) that was subsequently used
in the Dex release study.
3.1.2. Liposome size and ζ -potential
Table 3 presents the size and ζ -potential of each of the
produced liposome formulations. The incorporation of Chol
into the liposomes did not result in any signiﬁcant change in
the mean diameter of the extruded Dex-loaded liposomes.
The ζ - potential of the CLwas close to neutrality and no sig-
niﬁcant difference was observed due to incorporation of
Chol and Dex (formulations A–D); however, the ζ - potential
increased for the PEGylated liposomes (formulations E and
F). The particle size distribution of the liposomes prepared
in this study showed a monodisperse distribution and there
was no signiﬁcant change in particle size of the CLs and
DSPE–PEG-coated liposomes.
Table 2. Effect of varying the Dex and Chol concentrations in
Dex PL and EE
Formulation Dex:HSPC:Chol PL (mol/mol) EE (%)
A 0.25:2:0.0 0.49±0.10 26.38±3.89
B 0.50:2:0.0 0.41±0.01 11.09±2.50
C 0.25:2:0.1 0.31±0.06 17.01±5.21
D 0.25:2:1.0 0.00±0.00 0.27±0.20
Table 3. ζ -Potential and mean particle diameter of Dex-loaded
liposomes
Formulation ζ -Potential Size (nm)
A 0.04±2.68 123.53±6.60
B 2.69±1.00 135.63±10.25
C 5.84±4.54 122.90±3.76
D 1.43±1.56 122.23±19.18
E 20.00±1.25 113.50±5.11
F 22.50±3.40 103.70±17.74
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3.1.3. STEM and SEM of Dex-loaded liposomes
Figure 1 shows STEM and SEM images of the Dex-loaded
liposomes (formulations C and E). The liposomes in
formulation C (Figure 1A) aggregated more than the lipo-
somes in formulation E with DSPE–PEG (Figure 1B) at the
higher liposome concentration. Analysing the SEM image
of non-coated liposomes prepared with formulation
C (Figure 1C), it is clear that the liposomes were fused
to each other and were spread and ﬂattened at the
support surface. From Figure 1D, it was observed that
the DSPE–PEG liposomes presented a nano-scale size
and spherical shape.
3.1.4. Dex release from liposomes
The release proﬁle of Dex from the DSPE–PEG-coated
liposomes was performed in dialysis tubes for 21 days,
using formulation E. This time frame was selected in ac-
cordance with the culture time usually required to obtain
a complete osteogenic differentiation of MSCs in vitro.
The release proﬁle of Dex (Figure 2) showed an initial
burst release within 12 h. Following the initial release, a
slower release was observed until day 6. Afterwards,
Dex continued to be released at a slower but steady rate
until day 21.
3.2. Biological activity
3.2.1. Cell viability and proliferation assessment
Initially, the inﬂuence of Dex-loaded liposomes over
hBMSCs viability and proliferation was assessed using
standard cell biology protocols, i.e. MTS and PicoGreen
assays, respectively. In terms of cell viability, no signiﬁcant
differences were found between the standard TCPS_Osteo
and the TCPS_LipDex culture conditions for days 7
(Mann–Whitney U-test, p=0.409) and 21 (Mann–Whitney
U-test, p=0.766). TCPS_Osteo only displayed a signiﬁ-
cantly higher cell viability value than TCPS_LipDex
for day 14 of hBMSCs culture (Mann–Whitney U-test,
p< 0.001) (Figure 3). Additionally, no signiﬁcant differ-
ences were observed over time in standard TCPS_Osteo
(Kruskal–Wallis test, p=0.022) and in the TCPS_LipDex
test condition (Kruskal–Wallis test, p=0.067).
In terms of DNA concentration, no signiﬁcant difference
between TCPS_Osteo and TCPS_Lip was found on days 7
(Mann–Whitney U-test, p=0.932), 14 (Mann–Whitney
U-test, p=0.755) and 21 (Mann–Whitney U-test,
p=0.989) (Figure 4). No signiﬁcant differences were found
between culture times in TCPS_Osteo (Kruskal–Wallis test,
p=0.945) and TCPS_Lip (Kruskal–Wallis test, p=0.919).
Figure 1. STEM and SEM images of Dex-loaded liposomes.
STEM: (A) formulation C; (B) formulation E. SEM: (C) uncoated
liposomes, formulation C; (D) DSPE–PEG-coated liposomes,
formulation E
Figure 2. In vitro cumulative Dex release from DSPE–PEG lipo-
somes (formulation E)
Figure 3. Box plot of hBMSCs viability (MTS assay) cultured on
TCPS_Osteo and TCPS_LipDex after 7, 14 and 21 days. Data were
analysed non-parametrically by Mann–Whitney U-test (*p<0.01
vs TCPS_Osteo)
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3.2.2. Alkaline phosphatase activity quantiﬁcation
In order to assess the onset of osteoblastic activity of the
cultured hBMSCs, the quantiﬁcation of the enzyme alka-
line phosphatase was performed according to a standard
method, the p-nitrophenol assay.
Importantly, the TCPS_LipDex test condition displayed a
signiﬁcantly higher ALP activity than the standard
TCPS_Osteo condition already at day 7 of hBMSCs culture
(Mann–Whitney U-test, p< 0.001) (Figure 5). However,
no signiﬁcant differences were found between TCPS_Osteo
and TCPS_LipDex for day 14 (Mann–Whitney U-test,
p=0.107) and 21 (Mann–Whitney U-test, p=0.710) of
hBMSCs culture. Additionally, no signiﬁcant differences
were found between culture days in the TCPS_LipDex test
condition (Kruskal–Wallis test, p=0.906). Conversely, in
the standard TCPS_Osteo condition, day 14 displayed a sig-
niﬁcantly higher ALP activity than day 7 (Kruskal–Wallis
test, Tukey’s HSD test, p< 0.001), and day 21 displayed a
signiﬁcantly higher ALP activity than days 7 and 14 of
hBMSCs culture (Kruskal–Wallis test, Tukey’s HSD test,
p< 0.001), suggesting that the differentiation takes longer
to be induced and follows a more sequential pattern.
3.2.3. Genotypic and phenotypic expression of
earlier osteoblastic markers
In a ﬁrst attempt to characterize the expression of the
osteoblastic proteins Osteopontin and Osteocalcin, both
involved in the homeostasis of bone tissue, an
immunolocalization procedure was conducted. As noticed
by the strongest intensity of the brownish staining
(Figure 6), hBMSCs cultured in the presence of Dex-loaded
liposomes showed protein expression of Osteopontin and
Osteocalcin earlier in time (i.e. 7 days of culture) than
hBMSCs cultured under standard osteogenic differentiation
conditions. This protein expression pattern was maintained
until day 14 of hBMSCs culture, decreasing for longer time
periods (i.e. 21 days) in both culture conditions.
Regarding the quantitative expression of osteoblastic
RNA transcripts (Figure 7), the alkaline phosphatase
(ALP) gene presented no signiﬁcant differences between
the standard TCPS_Osteo and the TCPS_LipDex culture
conditions for days 7 (Mann–Whitney U-test, p=0.285),
14 (Mann–WhitneyU-test, p=0.285) and21 (Mann–Whitney
U-test, p=0.068). For the osteopontin (OP) gene, also no
signiﬁcant difference between TCPS_Osteo and TCPS_
LipDex was found on days 7 (Mann–Whitney U-test,
p=0.685), 14 (Mann–Whitney U-test, p=0.845) and 21
(Mann–Whitney U-test, p=0.285) of hBMSCs culture. For
the osteocalcin (OCN) gene, no signiﬁcant difference
betweenTCPS_Osteo and TCPS_LipDex was found for days
7 (Mann–Whitney U-test, p=0.685), 14 (Mann–Whitney
U-test, p=0.715) and 21 (Mann–Whitney U-test, p=0.109).
Concerning the expression of the transcriptional factor
Runx2, no signiﬁcant difference between TCPS_Osteo and
TCPS_LipDex was found on days 7 (Mann–Whitney U-test,
p=0.465), 14 (Mann–Whitney U-test, p=0.465) and 21
(Mann–Whitney U-test, p=0.285). In theOsterix transcrip-
tional factor, no signiﬁcant differences were also found
between TCPS_Osteo and TCPS_LipDex for days 7
(Mann–Whitney U-test, p=0.465), 14 (Mann–Whitney
U-test, p=0.068) and 21 (Mann–Whitney U-test, p=0.068)
of hBMSCs culture.
4. Discussion
4.1. Development and characterization of
Dex-loaded liposomes
The use of liposomes as a biological drug carrier has sev-
eral advantages for tissue engineering and regenerative
medicine (Kulkarni et al., 2010): liposomes have the great
Figure 4. Box plot of the DNA concentration (μg/ml) in
TCPS_Osteo and TCPS_Lip after 7, 14 and 21 days of culture. Data
were analysed non-parametrically by Mann–Whitney U-test
Figure 5. Box plot of ALP activity (μM/h/μg protein) in
TCPS_Osteo and TCPS_LipDex after 7, 14 and 21 days of culture.
Data were analysed non-parametrically by Mann–Whitney U-test
(*p<0.01 vs TCPS_Osteo)
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advantage of being generally non-toxic for cells; they can
be used to encapsulate both hydrophilic and lipophilic
growth or differentiation factors, using the bilayer com-
partment and the inner core for release of the contents
directly into the site of action; and it is possible to control
the release of growth or differentiation factors by
adjusting the liposomal formulation and applying differ-
ent stimuli, such as pH (Kale and Torchilin, 2007),
temperature (Bhardwaj and Burgess, 2010), ultrasonic
waves (Leong-Poi et al., 2007), magnetic ﬁelds (Zheng
et al., 2009) and light (Wu et al., 2008). A critical design
parameter in the formulation of liposomes is the maxi-
mum amount of PEG-lipids that can be incorporated into
the phospholipid bilayer before its conversion into a mi-
celle (Hristova et al., 1995). This coating provides steric
stabilization to the liposomes, which limits opsonization
as well as direct interactions with cells, most importantly
in the reticuloendothelial system (Allen et al., 1991).
Moreover, the liposomes have the advantage of forming
more stable formulations and are able to retain the encap-
sulated drug more efﬁciently. HSPC was selected because
it has a high phase transition temperature, Tc=52°C
(Drummond et al., 1999). The presence of Chol has a rel-
evant role in maintaining liposomal bilayer stability. The
use of steric stabilization coatings makes the need for
Chol less relevant for liposome assembly, although its
use gains relevance for the assembly of drug-loaded lipo-
somes, due to their capability to stabilize the drug inside
the loaded liposomes.
In the Dex-loading liposome formulation optimization
study, an inverse correlation of the system PL and EE with
Chol concentration was observed (Table 2). The encapsu-
lation of Dex was highest when no Chol was added to the
liposome formulation. A possible explanation for this
observation is the competitive encapsulation of Dex and
Chol for the same sites within the liposome structure,
with a clear advantage for Chol with respect to Dex. In
this perspective, Dex is displaced from the positions in
the membrane that are occupied by Chol. This may be re-
lated to the fact that the structures of the two compounds
are very similar. This result is in accordance with other
studies found in the literature (Tsotas et al., 2007;
Bhardwaj and Burgess, 2010). The different stabilizing
effects of Chol and Dex in the liposomes might be due to
Figure 6. Immunocytochemistry for osteopontin and osteocalcin, expressed by hBMSCs cultured on TCPS_Osteo and TCPS_Lip after
7, 14 and 21 days
Figure 7. Relative expression of bone-speciﬁc transcripts by
hBMSCs cultured on Dex-loaded liposomes for 7, 14 and 21 days,
normalized toTCPS_Osteo. Datawere analysed non-parametrically
by Mann–Whitney U-test
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differences in their interaction with the phospholipid mol-
ecules. The highly lipophilic Chol is incorporated between
acyl chains and reduces chain movement (increasing
rigidity) above the phase transition temperature. There-
fore, Chol shows membrane stabilization above the phase
transition temperature. Dex, being more hydrophilic,
may interact differently with the phospholipid acyl chains
and head groups and may destabilize the membrane
(Bhardwaj and Burgess, 2010).
The liposomes prepared in this study showed a mono-
disperse distribution. The ζ - potential increased for
PEGylated liposomes (formulations E and F, Table 3).
The ζ -potential of liposomes is negative due to the pres-
ence of terminal carboxylic groups in the lipids. The value
of the ζ -potential for PEGylated liposomes was one order
of magnitude lower, due to the negatively-charged phos-
phate group of DSPE–PEG, thus eliciting a reduced
electrophoretic mobility and a high-energy barrier that
avoids agglomeration and stabilizes the nanosuspension
(Youseﬁ et al., 2008).
When liposomes hit a suitable and solid surface, they
may adsorb, break and spread to form a bilayer on a
hydrophilic surface or a monolayer on a hydrophobic
one (Jass et al., 2000). An SEM image of non-coated lipo-
somes prepared with formulation C (Figure1C) showed
that the liposomes fused to each other, spread and
ﬂattened on the support surface. As the major structural
components of cell membranes, phospholipids are criti-
cally important in membrane fusion processes. The bilayer
structure and its physical properties (e.g. bilayer dehydra-
tion, lipid composition, lipid packing, bilayer curvature
and non-bilayer phases) can contribute to membrane
fusion. Hydration of the lipid head groups is also an
important parameter in membrane fusion. These groups
are hydrophilic and a shell of water is associated with
the liposomal surface, representing a barrier to membrane
fusion. Therefore, by removing the water from the head
groups, the liposomes can lose their structures and
fuse to each other. In conclusion, the incorporation of
the DSPE–PEG in the liposomes helps to maintain the
hydrated head groups, inducing the stabilization of the
liposome structure.
An essential point in the evaluation of drug-delivery
systems is the rate at which the drug is released from
the carrier, predicting their in vivo behaviour. The release
proﬁle of Dex (Figure 2) showed an initial burst release,
although Dex continued to be released at a slower but
steady rate until day 21. Similar results were obtained in
other studies found in the literature (Tsotas et al., 2007;
Bhardwaj and Burgess, 2010), in which Dex release kinetics
from different types of liposomes were studied. It was
found that Dex kinetic release is dependent on release,
extrusion and lipid transition temperatures. Dex release
from extruded liposomes was fast and most of the contents
were released within 48 h at 37°C. A slower release was
found from DSPC which, according to the aforementioned
studies, could be explained by the high transition tempera-
ture (Tc=42°C). Indeed, in this study we also used HSPC in
the liposome formulation, which has a Tc=52°C.
4.2. Biological activity of Dex released from
liposomes
The osteogenic differentiation factor herein incorporated
into the optimized liposomes formulation was previously
studied by our group in different drug-release systems,
including micro- and nanoparticles and nanoﬁbrous and
macroporous scaffolds (Balmayor et al., 2008, 2009b,
Oliveira et al., 2008, 2009, 2010; Duarte et al., 2009).
Herein, the effect of Dex-loaded liposomes on viability,
proliferation, protein synthesis and osteogenic differentia-
tion of hBMSCs was assessed by the use of standard
research methods. Biological data show an earlier induc-
tion of hBMSCs differentiation into the osteogenic line-
age, i.e. at day 7 of culture, as depicted by the results of
ALP activity, osteoblastic protein expression and transcript
expression patterns (i.e. immunocytochemistry and qPCR
data). This observation is of signiﬁcant relevance when
compared with standard culture conditions for in vitro in-
duction of hBMSCs osteogenic differentiation, demon-
strating similar expression patterns to the TCPS_LipDex
test condition for longer culture periods (i.e. for 14 and
21 days). This effect of time on the induction of osteo-
genic differentiation does not affect hBMSCs viability,
demonstrating the absence of a toxicity effect by the
Dex-loaded liposomes, but retards its proliferative capa-
bility, as depicted by the quantitative data from MTS
and PicroGreen assays, respectively. Indeed, it is expected
that an earlier differentiation may affect the proliferative
potential of the cells.
Dexamethasone, besides being a differentiation factor,
is also a well-known glucocorticoid, effectively used to
attenuate inﬂammation in different clinical conditions,
but with severe side-effects. Therefore, the local delivery
of glucocorticoids by liposomes could be beneﬁcial in
various therapies (Asgeirdottir et al., 2007; Hegeman
et al., 2011). Liposomes encapsulating this compound
have shown to exert strong beneﬁcial effects in inﬂamma-
tory diseases (Hegeman et al., 2011), such as atheroscle-
rosis (Chono and Morimoto, 2006) and osteoarthritis
(Elron-Gross et al., 2009), and it has been evaluated in an-
imal models of multiple sclerosis and Crohn’s disease
(Crielaard et al., 2011). The efﬁcacy of Dex incorporated
into liposomes in the treatment of atherosclerosis, the up-
take of Dex-loaded liposomes by macrophages and foam
cells and its inhibitory effect on cellular cholesterol ester
accumulation in these cells have already been investi-
gated in vitro (Chono and Morimoto, 2006). Besides the
aforementioned studies, no studies have been published
exploring these Dex-releasing biological nanoparticles or
liposomes as a strategy to induce MSCs differentiation,
in vitro or in vivo.
The approach described here constitutes an effective
in vitro strategy to ameliorate the osteogenic differentia-
tion of hBMSCs in time. Generally, under standard differ-
entiation conditions, hBMSCs take 14–21 days to fully
differentiate into the osteogenic lineage, which is time
consuming (Jaiswal et al., 1997). With LipDex culture
medium supplementation, the hBMSCs are differentiated
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into the osteogenic lineage at day 7 without compromis-
ing the viability and proliferation of the cells. Therefore,
LipDex culture medium supplementation comprises a
time-saving strategy when a stem cell-based therapy is
envisioned for a predeﬁned clinical situation. This time-
effective strategy of hBMSCs induction of differentiation
could be transposed to other tissue-engineering and
regenerative approaches, e.g. to the implantation of
biofunctionalized scaffolds with surface-immobilized
Dex-loaded liposomes, or by their direct injection at the
injury site, to induce the differentiation of local or circu-
lating MSCs in vivo. This is possible due to the capability
of the liposomes to release this bioactive agent near to,
or even internalize it into, the hBMSCs (Chono and
Morimoto, 2006).
5. Conclusion
We propose liposomes as a differentiation factor release
system to promote the osteogenesis of hBMSCs. The re-
lease proﬁle of Dex showed an initial burst release,
followed by a slower but steady release rate until day
21. We conclude that liposomes are non-cytotoxic. Our
data shows that the release of Dex from liposomes pro-
motes an earlier osteogenic differentiation of hBMSCs.
The phenotypic and genotypic results are comparable.
We believe that this result may have interesting implica-
tions for the development of cell-based therapies for bone
regeneration in the context of autologous approaches.
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